Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG-PET

Movement Disorders

Volumn 16, Issue 6, 2001, Pages 1014-1022

  Berding, Georg ^a   Odin, Per ^b   Brooks, David J ^c   Nikkhah, Guido ^a   Matthies, Cordula ^a   Peschel, Thomas ^a   Shing, Mona ^a,b   Kolbe, Hans ^a   van den Hoff, Jörg ^a   Fricke, Harald ^a   Dengler, Reinhard ^a   Samii, Madjid ^a   Knapp, Wolfram H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Advanced Parkinson's disease; Dementia; Dopamine treatment; FDG; Positron emission tomography

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; LEVODOPA;

ADULT; AGE; AGED; BLOOD SAMPLING; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; IMAGE ANALYSIS; MALE; METABOLIC DISORDER; ON OFF PHENOMENON; ORBITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REST; REVIEW; STATISTICAL PARAMETERS; TEMPORAL LOBE; THALAMUS; TREATMENT WITHDRAWAL; VENOUS BLOOD;

ADULT; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035526323     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1212     Document Type: Review

References (53)

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. New Engl J Med 1998;339:1044-1051.
2. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. New Engl J Med 1998;339:1130-1143.
3. Wooten GF, Collins RC. Metabolic effects of unilateral lesions of substantia nigra. J Neurosci 1981;1:285-291.
4. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
5. Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, Chase TN. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. Can J Neurol Sci 1992; 19:163-169.
6. 18F]fluorodeoxyglucose method. Ann Neurol 1984;15:419-424.
7. Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB. Cortical glucose metabolism in Parkinson's and Alzheimer disease. J Neurosci Res 1990;27:561-568.
8. Turjanski N, Brooks DJ. PET and the investigation of dementia in the parkinsonian patient. J Neural Trasm 1997;51:37-48.
9. Huges AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathological study of 100 cases in Parkinson's disease. Arch Neurol 1993;50: 140-148.
10. Tison F, Dartigues JF, Auriacombe S, Letenneur S, Boller F, Alperovitch A. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995;45:705-708.
11. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999;52:541-546.
12. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust W. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994;15:329-335.
13. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, Fahn S. The metabolic topography of parkinsonism. J Cereb Blood Flow Meabol 1994;14:783-801.
14. 18FDG-PET study. Brain 2000; 123:340-352.
15. Arahata Y, Hirayama M, Ieda T, Koike Y, Kato T, Tadokoro M, Ikeda M, Ito K, Sobue G. Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure. J Neurol Sci 1999, 163:119-126.
16. 18F-FDG. Ann Nucl Med 1997;11:251-257.
17. Broussolle E, Cinotti L, Pollak P, Landais P, Le Bars D, Galy G, Lavenne F, Khalfallah Y, Chazot G, Mauguiere F. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease. Mov Disord 1993;8:459-462.
18. Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causon R, Jones T, Legg NJ. The effect of L-Dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 1985;108:171-191.
19. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;111:299-321.
20. Kulisevsky J, Avial A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132.
21. Poewe W, Berger W, Benke T, Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991;29:670-673.
22. Ruzicka E, Roth J, Spackova N, Mecir P, Jech R. Apomorphine induced cognitive changes in Parkinson's disease. J Neurol Psychiatry 1994;57:998-1001.
23. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologica 2000;38:596-612.
24. Frey KA, Minoshima S, Kuhl DE. Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Q J Nucl Med 1998;42:166-178.
25. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995;9:6-16.
26. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karatsu TE, editors. New York: Grune and Stratton; 1976. p 77-121.
27. Hoehn MM, Yahr MD. Parkinsonism. Onset, progression and mortality. Neurology 1967;17:427-442.
28. Fahn S, Elton RL, Members of the UPDRS development commitee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease, volume 2. Florham Park, New Jersey: Macmillan; 1987. p 293-304.
29. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
30. Blomqvist G. On the construction of functional maps in positron emission tomography. J Cereb Blood Flow Metabol 1984;4:629-632.
31. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
32. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
33. 18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999;9:63-80.
34. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Thieme, Stuttgart, New York; 1988.
35. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000;54: 1482-1487.
36. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson's disease: [18F]fluorodopa positron emission tomography. Arch Neurol 2000;57:470-475.
37. Daum I, Schugens MM, Spieker S, Poster U, Schonle PW, Birbaumer N. Memory skill acquistions in Parkinson's disease and frontal lobe dysfunction. Cortex 1995;31:413-432.
38. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115: 1727-1751.
39. Taylor AE, Sain-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain 1986;109:845-883.
40. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med 1996;37:1115-1122.
41. Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, Eidelberg D. Differential diagnosis of Parkinsonism with [18F]Fluorodeoxyglucose and PET. Mov Disord 1998;13: 268-274.
42. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a positron emission tomography and [11C]raclopride. Mov Disord 1997; 12:33-38.
43. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
44. Bowen FP, Kamienny RS, Burns MM, Yahr M. Parkinsonism: effects of levodopa treatment on concept formation. Neurology 1975;25:701-704.
45. Cooper A, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1992;115:1701-1725.
46. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, Parkinson study group. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology 1998;50:1327-1331.
47. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992;107:394-404.
48. Dias R, Robbins TW, Roberts AC. Dissociation in prefrontal cortex of affective and attentional shifts. Nature 1996;380:69-72.
49. Rahman S, Sahakian BJ, Hodges JR, Rogers RD, Robbins TW. Specific cognitive deficits in mild frontal variant frontotemporal dementia. Brain 1999;122:1469-1493.
50. Hoffman SW, Fulop Z, Stein DG. Bilateral frontal cortical contusion in rats:behavioral and anatomic consequences. J Neurotrauma 1994;11:417-431.
51. Kalashnikova LA, Gulevskaya TS, Kashina EM. Disorders of higher mental function due to single infarctions in the thalamus and in the area of thalamoftontal tracts. Neurosci Behav Physiol 1999; 29:397-403.
52. Van der Werf YD, Weerts JG, Jolles J, Witter MP, Lindeboom J, Scheltens P. Neuropsychological correlates of a right unilateral lacunar thalamic infarction. J Neurol Neurosurg Psychiatry 1999; 66:36-42.
53. Forstl H, Sahakian B. Thalamic radiodensity and cognitive performance in mild and moderate dementia of the Alzheimer type. J Psychiatry Neurosci 1993; 18:33-37.